Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever. Earlier this week, Novo Nordisk tore up a partnership with the telehealth storefront Hims & Hers Health,

INDIANAPOLIS, Ind. - Eli Lilly and Company, a major pharmaceutical company, announced on Monday that its weight-loss drug, Zepbound, will soon be cheaper for people who pay for it themselves, without relying on insurance.

Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker struggles to fend off rivals in the burgeoning weight-loss market it helped pioneer.

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage for it.